Announcements
- Annual General Meeting of Kuros Biosciences approves all resolutions
- Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
- Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
- Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
- Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 7.58 |
Average volume | 11.03k |
---|---|
Shares outstanding | 36.87m |
Free float | 23.88m |
P/E (TTM) | -- |
Market cap | 277.97m CHF |
EPS (TTM) | -0.3697 CHF |
Data delayed at least 20 minutes, as of Apr 19 2024 16:00 BST.
More ▼